Sunshine Biopharma Inc. (SBFM): Price and Financial Metrics

Sunshine Biopharma Inc. (SBFM): $0.77

-0.02 (-2.09%)

POWR Rating

Component Grades













SBFM Stock Price Chart Interactive Chart >

Price chart for SBFM

SBFM Price/Volume Stats

Current price $0.77 52-week high $15.60
Prev. close $0.79 52-week low $0.62
Day low $0.75 Volume 132,000
Day high $0.80 Avg. volume 3,675,301
50-day MA $0.83 Dividend yield N/A
200-day MA $1.66 Market Cap 17.50M

Sunshine Biopharma Inc. (SBFM) Company Bio

Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. Its products include treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Pointe-Claire, Canada.

SBFM Latest News Stream

Event/Time News Detail
Loading, please wait...

SBFM Latest Social Stream

Loading social stream, please wait...

View Full SBFM Social Stream

Latest SBFM News From Around the Web

Below are the latest news stories about SUNSHINE BIOPHARMA INC that investors may wish to consider to help them evaluate SBFM as an investment opportunity.

NASDAQ: SBFM 👥 Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! 🔬

Christine Petraglia - TraDigital IR

Yahoo | November 23, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!

William White on InvestorPlace | November 21, 2022

Sunshine Biopharma Collaborates For Its Lead mRNA-Based Cancer Program

Sunshine Biopharma Inc (NASDAQ: SBFM) has entered into a collaboration agreement with a North American lipid nanoparticle (LNP) company to advance the development of its mRNA-based anticancer macromolecule, K1.1. The company's collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma's in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma previously showed that its K1.1 mRNA could destroy cancer cells in vitro, including multidrug-resistant breast

Yahoo | November 16, 2022

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (“LNP”) companies. The purpose of the collaboration is to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1. Th

Yahoo | November 16, 2022

Sunshine Biopharma Third Quarter 2022 Earnings: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)

Sunshine Biopharma ( NASDAQ:SBFM ) Third Quarter 2022 Results Key Financial Results Net loss: US$1.46m (loss narrowed...

Yahoo | November 13, 2022

Read More 'SBFM' Stories Here

SBFM Price Returns

1-mo -5.23%
3-mo -28.70%
6-mo -36.89%
1-year -92.80%
3-year -61.50%
5-year -99.90%
YTD -93.42%
2021 272.61%
2020 57.00%
2019 -96.88%
2018 -93.28%
2017 197.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6 seconds.